Table 4.
Participants With Event, n (%) | Placebo (N = 59) | Atogepant 300 mg (N = 60) | Moxifloxacin 400 mg (N = 59) |
---|---|---|---|
Any TEAE | 3 (5.1) | 1 (1.7) | 8 (13.6) |
Serious TEAE | 0 | 0 | 0 |
Treatment‐related TEAE | 0 | 0 | 0 |
TEAE leading to discontinuation | 0 | 0 | 0 |
TEAE, treatment‐emergent adverse event.